In Memoriam; by Alfred, Lord Tennyson; A Photographic Interpretation

In Memoriam; by Alfred, Lord Tennyson; A Photographic Interpretation is a photographic essay completed by Eunice Blanchard in 1947 as an English Term Paper at Syracuse University in Syracuse, NY. Blanchard tells the story of Tennyson\u27s poem through original photography. Acknowledgements: Arthur W. Brown, Instructor in English; C. Wesley Brewster, Instructor in Photography; D.M. Norton, Assistant to Mr. Brewster; Photography Models: Janet Clark, Betty Sanders, Aubrey Vaughn Woolsey. Jr. This is the original work of Eunice Blanchard, under CCBY 4.0. It is an open-access work, copyrighted and licensed by the author for re-use

Dynamic optimization of dual-mode hybrid systems with state-dependent switching conditions

This paper presents a computational approach for optimizing a class of hybrid systems in which the state dynamics switch between two distinct modes. The times at which the mode transitions occur cannot be specified directly, but are instead governed by a state-dependent switching condition. The control variables, which should be chosen optimally by the system designer, consist of a set of continuous-time input signals. By introducing an auxiliary binary-valued control function to represent the system's current mode, we show that any dual-mode hybrid system with state-dependent switching conditions can be transformed into a standard dynamic system subject to path constraints. We then develop a computational algorithm, based on control parameterization, the time-scaling transformation, and an exact penalty method, for determining the optimal piecewise constant input signals for the original hybrid system. A numerical example on cancer chemotherapy is included to demonstrate the effectiveness of the proposed algorithm

Optimal control of impulsive switched systems with minimum subsystem durations

This paper presents a new computational approach for solving optimal control problems governed by impulsive switched systems. Such systems consist of multiple subsystems operating in succession, with possible instantaneous state jumps occurring when the system switches from one subsystem to another. The control variables are the subsystem durations and a set of system parameters influencing the state jumps. In contrast with most other papers on the control of impulsive switched systems, we do not require every potential subsystem to be active during the time horizon (it may be optimal to delete certain subsystems, especially when the optimal number of switches is unknown). However, any active subsystem must be active for a minimum non-negligible duration of time. This restriction leads to a disjoint feasible region for the subsystem durations. The problem of choosing the subsystem durations and the system parameters to minimize a given cost function is a non-standard optimal control problem that cannot be solved using conventional techniques. By combining a time-scaling transformation and an exact penalty method, we develop a computational algorithm for solving this problem. We then demonstrate the effectiveness of this algorithm by considering a numerical example on the optimization of shrimp harvesting operations

Distinct Kinetics of Memory B-Cell and Plasma-Cell Responses in Peripheral Blood Following a Blood-Stage Plasmodium chabaudi Infection in Mice

B cell and plasma cell responses take place in lymphoid organs, but because of the inaccessibility of these organs, analyses of human responses are largely performed using peripheral blood mononuclear cells (PBMC). To determine whether PBMC are a useful source of memory B cells and plasma cells in malaria, and whether they reflect Plasmodium-specific B cell responses in spleen or bone marrow, we have investigated these components of the humoral response in PBMC using a model of Plasmodium chabaudi blood-stage infections in C57BL/6 mice. We detected memory B cells, defined as isotype-switched IgD− IgM− CD19+ B cells, and low numbers of Plasmodium chabaudi Merozoite Surface Protein-1 (MSP1)-specific memory B cells, in PBMC at all time points sampled for up to 90 days following primary or secondary infection. By contrast, we only detected CD138+ plasma cells and MSP1-specific antibody-secreting cells within a narrow time frame following primary (days 10 to 25) or secondary (day 10) infection. CD138+ plasma cells in PBMC at these times expressed CD19, B220 and MHC class II, suggesting that they were not dislodged bone-marrow long-lived plasma cells, but newly differentiated migratory plasmablasts migrating to the bone marrow; thus reflective of an ongoing or developing immune response. Our data indicates that PBMC can be a useful source for malaria-specific memory B cells and plasma cells, but extrapolation of the results to human malaria infections suggests that timing of sampling, particularly for plasma cells, may be critical. Studies should therefore include multiple sampling points, and at times of infection/immunisation when the B-cell phenotypes of interest are likely to be found in peripheral blood

Exact penalty methods for nonlinear optimal control problems

Research comprised of developing solution techniques to three classes of non-standard optimal control problems, namely: optimal control problems with discontinuous objective functions arising in aquaculture operations; impulsive optimal control problems with minimum subsystem durations; optimal control problems involving dual-mode hybrid systems with state-dependent switching conditions. The numerical algorithms developed involved an exact penalty approach to transform the constrained problem into an unconstrained problem which was readily solvable by a standard optimal control software

Part 9: First Aid: 2015 International Consensus on First Aid Science With Treatment Recommendations

status: publishe

426. COVID-19 Infection Prevention Practices That Exceed CDC Guidance: Balancing Extra Caution Against Impediments to Care

Abstract Background At the outset of the COVID-19 pandemic, healthcare workers (HCWs) raised concerns about personal risks of acquiring infection during patient care. This led to more stringent infection prevention practices than CDC guidelines during a time of uncertainty about transmission and limited U.S. testing capacity. Hospitals were challenged to protect against true COVID-19 exposure risks, while avoiding use of unproven measures that could interfere with timely, high quality care. We evaluated hospital experiences with HCW COVID-19 exposure concerns impacting clinical workflow/management. Methods We conducted a 32-question structured survey of hospital infection prevention leaders (one per hospital) from CDC Prevention Epicenters, University of California (CA) Health system, HCA Healthcare, and the Southern CA Metrics Committee between May–Dec, 2020. We assessed facility characteristics and COVID-19 exposure concerns causing changes in respiratory care, procedure delays/modifications, requests to change infection prevention processes, disruptions in routine medical care, and health impacts of PPE overuse. Percentages were calculated among respondents for each question. Results Respondents represented 53 hospitals: 22 (42%) were small (< 200 beds), 14 (26%) medium (200-400 beds), and 17 (32%) large ( >400 beds) facilities. Of these, 11 (21%) provided Level 1 trauma care, and 22 (41%) provided highly immunocompromised patient care; 75% had cared for a substantial number of COVID-19 cases before survey completion. Majority reported changes in respiratory care delivery (71%-87%), procedural delays (75%-87%), requests to change infection prevention controls/protocols (58%-96%), and occupational health impacts of PPE overuse including skin irritation (98%) and carbon dioxide narcosis symptoms (55%) (Table). Conclusion HCW concerns over work-related COVID-19 exposure contributed to practice changes, many of which are unsupported by CDC guidance and resulted in healthcare delivery delays and alterations in clinical care. Pandemic planning and response must include the ability to rapidly develop evidence to guide infection prevention practice. Disclosures Shruti K. Gohil, MD, MPH, Medline (Other Financial or Material Support, Co-Investigator in studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products)Molnycke (Other Financial or Material Support, Co-Investigator in studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products)Stryker (Sage) (Other Financial or Material Support, Co-Investigator in studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products) Edward Septimus, MD, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic products)Molnlycke (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic products) Kenneth Sands, MD, MPH, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Eunice J. Blanchard, MSN RN, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Julia Moody, MS, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product)Molnlycke (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Deborah S. Yokoe, MD, MPH, Nothing to disclose Jonathan Grein, MD, Gilead (Other Financial or Material Support, Speakers fees) Stuart H. Cohen, MD, Seres (Research Grant or Support) Kimberly N. Smith, MBA, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Brandon Carver, BA, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Russell Poland, PhD, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Jonathan B. Perlin, MD, PhD, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product)Molnlycke (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Richard Platt, MD, MSc, Medline (Research Grant or Support, Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product)Molnlycke (Other Financial or Material Support, Conducted studies in which participating hospitals received contributed antiseptic product) Susan S. Huang, MD, MPH, Medline (Other Financial or Material Support, Conducted studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products)Molnlycke (Other Financial or Material Support, Conducted studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products)Stryker (Sage) (Other Financial or Material Support, Conducted studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products)Xttrium (Other Financial or Material Support, Conducted studies in which participating hospitals and nursing homes received contributed antiseptic and cleaning products